<DOC>
	<DOCNO>NCT00592774</DOCNO>
	<brief_summary>The purpose study determine efficacy safety Perampanel ( E2007 ) patient Post-Herpetic Neuralgia ( PHN ) .</brief_summary>
	<brief_title>Dose-Tolerability Titration Study Evaluate The Efficacy And Safety Of Perampanel ( E2007 ) In Patients With Post-Herpetic Neuralgia ( PHN )</brief_title>
	<detailed_description />
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Neuralgia , Postherpetic</mesh_term>
	<criteria>To include , patient must meet following : 1 . Provide write informed consent , prior enter study undergo study procedure . 2 . Male female patient ≥18 year age . Females either nonchildbearing potential result surgery menopause ( 1 year onset ) , childbearing potential practicing medically acceptable method contraception . Acceptable contraception include : abstinence , barrier method plus spermicide , intrauterine device [ IUD ] . Those female use hormonal contraceptive must also use additional approve method contraception ( e.g. , barrier method plus spermicide IUD ) . Contraceptive use must start least 1 month Visit 1 , practice throughout entire study period , continue 1 month end study . They must also negative serum betahuman chorionic gonadotropin ( βhCG ) Visit 1 , negative urine pregnancy test Baseline Visit 2 . 3 . PHN least 6 month duration ; onset PHN define time heal herpes zoster skin lesion . 4 . Pain past 6 month , clinically identifiable improve worsen trend , base medical history . 5 . Score ≥ 40 mm visual analog scale ( VAS ) short form McGill Pain Questionnaire ( SFMPQ ) Visit 1 Baseline ( Visit 2 prior randomization ) . 6 . Have complete patient diary least 6 7 day prior Visit 2 ( Baseline ) . 7 . Average daily pain score ≥ 4 , 11point Likert scale 7 day prior randomization [ diaries ] . 8 . Reliable willing able cooperate study procedure , include follow example : Accurately enter diary daily basis Returning study visit require date Accurately reliably report symptom ( include treatmentemergent sign symptom ) Taking study drug require protocol 9 . Be stable analgesic treatment ( medication ( ) ) stable nonpharmacological pain treatment least 4 week prior Visit 1 remain stable treatment throughout study . Nonpharmacologic pain treatment include follow : relaxation/hypnosis physical occupational therapy mentalhealth counsel acupuncture injection block , etc . Episodic periodic pharmacologic treatment monthly injection treatment pain ( eg , local anesthetic ) permit . Up 4 g acetaminophen/day permit rescue medication , need , trial . Patients follow exclude : 1 . Any condition could interfere conduct trial confound efficacy evaluation include follow example : pain neuropathy another cause ( include painful diabetic neuropathy ) , central pain , radiculopathy , painful arthritis , etc . 2 . Motivation secondary gain , negativeincentive achieve pain functional relief ( eg , litigation ) . This determined medical history discretion investigator . 3 . Inability cooperate protocol , reason . 4 . Clinically significant , progressive , potentially unstable disease body system include cardiovascular , gastrointestinal , CNS , psychiatric , endocrine , immunologic , include patient follow broad disease category : 1 . Systemic infection ( eg , human immunodeficiency virus [ HIV ] , hepatitis , tuberculosis [ TB ] , syphilis ) ; lack appropriate medical history condition acceptable , 2 . History past ( within past 12 month ) present drug alcohol abuse per Diagnostic Statistical Manual 4th Edition ( DSM IV ) criterion , 3 . History acute coronary syndrome within past 12 month , 4 . Active cancer within previous 5 year ( exception fully treat , nonmelanoma skin cancer basal cell carcinoma ) , 5 . Systemic chemotherapy immunotherapy within past 5 year , 6 . History major depression , bipolar disease , psychosis suicidal ideation attempt within past 5 year , 7 . History major systemic allergy anaphylactoid reaction StevensJohnson syndrome ( however , patient limit allergy contact dermatitis minor allergy penicillin acceptable ) . 5 . Any following laboratory abnormality Visit 1 : 1 . Clinically significant ECG abnormality , include prolonged QTc ( define QTcB &gt; 450 msec ) , 2 . Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) ≥ 1.5 time upper limit normal ( ULN ) , 3 . Clinically significant abnormal white blood cell ( WBC ) , absolute neutrophil , platelet count value , 4 . Any clinically significant laboratory value . 6 . Exposure investigational drug within 30 day prior Visit 1 exposure ever perampanel . 7 . Females pregnant , lactating , plan become pregnant study . 8 . Use medication know strong inducer CYP3A4 activity within 4 week prior Visit 1 ; use CYP3A4 inducer prohibit entire study duration .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Post-Herpetic Neuralgia</keyword>
	<keyword>PHN )</keyword>
</DOC>